Literature DB >> 8168010

Increased serum lithium levels due to ketorolac therapy.

R Langlois1, D Paquette.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8168010      PMCID: PMC1486635     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Ketorolac (Toradol): a new analgesic or an old NSAID?

Authors:  W Spickler
Journal:  CMAJ       Date:  1993-05-15       Impact factor: 8.262

2.  Ketorolac (Toradol): a marketing phenomenon.

Authors:  R E Ariano; S A Zelenitsky
Journal:  CMAJ       Date:  1993-05-15       Impact factor: 8.262

Review 3.  The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions.

Authors:  M Ragheb
Journal:  J Clin Psychopharmacol       Date:  1990-10       Impact factor: 3.153

4.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors:  J W Tetrud; J W Langston
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

5.  Selegiline as initial treatment in de novo parkinsonian patients.

Authors:  V V Myllylä; K A Sotaniemi; J A Vuorinen; E H Heinonen
Journal:  Neurology       Date:  1992-02       Impact factor: 9.910

  5 in total
  4 in total

Review 1.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 2.  Minimising the adverse effects of ketorolac.

Authors:  D I Reinhart
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

3.  Chronic lithium toxicity: Considerations and systems analysis.

Authors:  Nora MacLeod-Glover; Ryan Chuang
Journal:  Can Fam Physician       Date:  2020-04       Impact factor: 3.275

Review 4.  Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  J R Brouwers; P A de Smet
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.